N. Olsen and C. Stein, New drugs for rheumatoid arthritis, N Engl J Med, vol.350, pp.2167-2179, 2004.

L. Bang and G. Keating, Adalimumab, BioDrugs, vol.16, issue.2, pp.121-139, 2004.
DOI : 10.2165/00063030-200418020-00005

J. Davis, . Jr, D. Van-der-heijde, J. Braun, M. Dougados et al., Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial, Arthritis & Rheumatism, vol.44, issue.11, pp.3230-3236, 2003.
DOI : 10.1002/art.11325

S. Hanauer, B. Feagan, G. Lichtenstein, L. Mayer, S. Schreiber et al., Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial, The Lancet, vol.359, issue.9317, pp.1541-1549, 2002.
DOI : 10.1016/S0140-6736(02)08512-4

S. Targan, S. Hanauer, S. Van-deventer, L. Mayer, D. Present et al., A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor ?? for Crohn's Disease, New England Journal of Medicine, vol.337, issue.15, pp.1029-1035, 1997.
DOI : 10.1056/NEJM199710093371502

P. Mease, TNF?? therapy in psoriatic arthritis and psoriasis, Annals of the Rheumatic Diseases, vol.63, issue.7, pp.755-758, 2004.
DOI : 10.1136/ard.2004.020719

C. Leonardi, J. Powers, R. Matheson, B. Goffe, R. Zitnik et al., Etanercept as Monotherapy in Patients with Psoriasis, New England Journal of Medicine, vol.349, issue.21, pp.2014-2022, 2003.
DOI : 10.1056/NEJMoa030409

P. Lahdenne, P. Vahasalo, and V. Honkanen, Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study, Annals of the Rheumatic Diseases, vol.62, issue.3, pp.245-247, 2003.
DOI : 10.1136/ard.62.3.245

J. Keane, G. S. Wise, R. Mirabile-levens, E. Kasznica, J. Schwieterman et al., Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor ?????Neutralizing Agent, New England Journal of Medicine, vol.345, issue.15, pp.1098-1104, 2001.
DOI : 10.1056/NEJMoa011110

J. Gomez-reino, L. Carmona, V. Valverde, E. Mola, M. Montero et al., Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report, Arthritis & Rheumatism, vol.44, issue.Suppl 9, pp.2122-2127, 2003.
DOI : 10.1002/art.11137

T. Ellerin, R. Rubin, and M. Weinblatt, Infections and anti-tumor necrosis factor ? therapy, Arthritis & Rheumatism, vol.46, issue.11, pp.3013-3022, 2003.
DOI : 10.1002/art.11301

R. Wallis, M. Broder, J. Wong, and D. Beenhouwer, Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction, Clinical Infectious Diseases, vol.39, issue.8, pp.1254-1255, 2004.
DOI : 10.1086/424455

URL : http://cid.oxfordjournals.org/cgi/content/short/39/8/1254

J. Askling, C. Fored, L. Brandt, E. Baecklund, L. Bertilsson et al., Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden, Arthritis & Rheumatism, vol.63, issue.7, pp.1986-1992, 2005.
DOI : 10.1002/art.21137

G. Aversa, J. Punnonen, and J. De-vries, The 26-kD transmembrane form of tumor necrosis factor alpha on activated CD4+ T cell clones provides a costimulatory signal for human B cell activation, Journal of Experimental Medicine, vol.177, issue.6, pp.1575-1585, 1993.
DOI : 10.1084/jem.177.6.1575

J. Van-den-brande, H. Braat, G. Van-den-brink, H. Versteeg, C. Bauer et al., Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn???s disease, Gastroenterology, vol.124, issue.7, pp.1774-1785, 2003.
DOI : 10.1016/S0016-5085(03)00382-2

A. Lugering, M. Schmidt, N. Lugering, H. Pauels, W. Domschke et al., Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway, Gastroenterology, vol.121, issue.5, pp.1145-1157, 2001.
DOI : 10.1053/gast.2001.28702

V. Kindler, A. Sappino, G. Grau, P. Piguet, and P. Vassalli, The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection, Cell, vol.56, issue.5, pp.731-740, 1989.
DOI : 10.1016/0092-8674(89)90676-4

H. Kaneko, H. Yamada, S. Mizuno, T. Udagawa, Y. Kazumi et al., Role of tumor necrosis factor-alpha in Mycobacterium-induced granuloma formation in tumor necrosis factoralpha-deficient mice, Lab Invest, vol.79, pp.379-386, 1999.

M. Olleros, R. Guler, N. Corazza, D. Vesin, H. Eugster et al., Transmembrane TNF Induces an Efficient Cell-Mediated Immunity and Resistance to Mycobacterium bovis Bacillus Calmette-Guerin Infection in the Absence of Secreted TNF and Lymphotoxin-??, The Journal of Immunology, vol.168, issue.7, pp.3394-3401, 2002.
DOI : 10.4049/jimmunol.168.7.3394

T. Botha and B. Ryffel, Reactivation of Latent Tuberculosis Infection in TNF-Deficient Mice, The Journal of Immunology, vol.171, issue.6, pp.3110-3118, 2003.
DOI : 10.4049/jimmunol.171.6.3110

B. Saunders, H. Briscoe, and W. Britton, infection, Clinical & Experimental Immunology, vol.82, issue.2, pp.279-287, 2004.
DOI : 10.1111/j.1365-2249.2004.02518.x

URL : https://hal.archives-ouvertes.fr/hal-01068720

B. Saunders, S. Tran, S. Ruuls, J. Sedgwick, H. Briscoe et al., Transmembrane TNF Is Sufficient to Initiate Cell Migration and Granuloma Formation and Provide Acute, but Not Long-Term, Control of Mycobacterium tuberculosis Infection, The Journal of Immunology, vol.174, issue.8, pp.4852-4859, 2005.
DOI : 10.4049/jimmunol.174.8.4852

X. Mariette, D. Salmon, and . Group, French guidelines for diagnosis and treating latent and active tuberculosis in patients with RA treated with TNF blockers, Annals of the Rheumatic Diseases, vol.62, issue.8, pp.791-792, 2003.
DOI : 10.1136/ard.62.8.791

K. Winthrop, J. Siegel, J. Jereb, Z. Taylor, and M. Iademarco, Tuberculosis associated with therapy against tumor necrosis factor ??, Arthritis & Rheumatism, vol.52, issue.10, pp.2968-2974, 2005.
DOI : 10.1002/art.21382

P. Andersen, M. Munk, J. Pollock, and T. Doherty, Specific immune-based diagnosis of tuberculosis, The Lancet, vol.356, issue.9235, pp.1099-1104, 2000.
DOI : 10.1016/S0140-6736(00)02742-2

S. Arend, P. Andersen, K. Van-meijgaarden, R. Skjot, Y. Subronto et al., Detection of Active Tuberculosis Infection by T Cell Responses to Early???Secreted Antigenic Target 6???kDa Protein and Culture Filtrate Protein 10, The Journal of Infectious Diseases, vol.181, issue.5, pp.1850-1854, 2000.
DOI : 10.1086/315448

A. Lalvani, A. Pathan, H. Durkan, K. Wilkinson, A. Whelan et al., Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells, The Lancet, vol.357, issue.9273, pp.2017-2021, 2001.
DOI : 10.1016/S0140-6736(00)05115-1

L. Wang, M. Turner, R. Elwood, M. Schulzer, and J. Fitzgerald, A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements, Thorax, vol.57, issue.9, pp.804-809, 2002.
DOI : 10.1136/thorax.57.9.804

K. Ewer, J. Deeks, L. Alvarez, G. Bryant, S. Waller et al., Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak, The Lancet, vol.361, issue.9364, pp.1168-1173, 2003.
DOI : 10.1016/S0140-6736(03)12950-9

I. Brock, K. Weldingh, E. Leyten, S. Arend, P. Ravn et al., Specific T-Cell Epitopes for Immunoassay-Based Diagnosis of Mycobacterium tuberculosis Infection, Journal of Clinical Microbiology, vol.42, issue.6, pp.2379-2387, 2004.
DOI : 10.1128/JCM.42.6.2379-2387.2004

I. Brock, K. Weldingh, T. Lillebaek, F. Follmann, and P. Andersen, Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts, American Journal of Respiratory and Critical Care Medicine, vol.170, issue.1, pp.65-69, 2004.
DOI : 10.1164/rccm.200402-232OC

M. Harboe, A. Malin, H. Dockrell, H. Wiker, G. Ulvund et al., B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis, Infect Immun, vol.66, pp.717-723, 1998.

F. Berthet, P. Rasmussen, I. Rosenkrands, P. Andersen, and B. Gicquel, A Mycobacterium tuberculosis operon encoding ESAT-6 and a novel low-molecular-mass culture filtrate protein (CFP- 10). Microbiology, pp.3195-3203, 1998.

Y. Levy, C. Durier, R. Krzysiek, C. Rabian, C. Capitant et al., Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection, AIDS, vol.17, issue.3, pp.343-351, 2003.
DOI : 10.1097/00002030-200302140-00008

A. Rimaniol, G. Garcia, S. Till, F. Capel, G. Gras et al., Evaluation of CD4+ T cells proliferating to grass pollen in seasonal allergic subjects by flow cytometry, Clinical and Experimental Immunology, vol.91, issue.1, pp.76-80, 2003.
DOI : 10.1046/j.1365-2222.2002.01281.x

E. Keystone, M. Schiff, J. Kremer, S. Kafka, M. Lovy et al., Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.23, issue.2, pp.353-363, 2004.
DOI : 10.1002/art.20019

S. Clair, E. Wagner, C. Fasanmade, A. Wang, B. Schaible et al., The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial, Arthritis & Rheumatism, vol.49, issue.6, pp.1451-1459, 2002.
DOI : 10.1002/art.10302

L. Berg, J. Lampa, S. Rogberg, R. Van-vollenhoven, and L. Klareskog, Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors, Annals of the Rheumatic Diseases, vol.60, issue.2, pp.133-139, 2001.
DOI : 10.1136/ard.60.2.133

D. Ponce-de-leon, E. Acevedo-vasquez, A. Sanchez-torres, M. Cucho, J. Alfaro et al., Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis, Annals of the Rheumatic Diseases, vol.64, issue.9, pp.1360-1361, 2005.
DOI : 10.1136/ard.2004.029041

J. Greenberg, S. Schloss, O. Kurucz, S. Reddy, V. Abellana et al., Pilot Study of Tuberculosis Screening Strategies for Rheumatoid Arthritis Patients [abstract], Arthritis Rheum, vol.52, p.545, 2005.

O. Shea, F. Kavanagh, P. Cassidy, A. Anwar, A. Mccarthy et al., The impact of steroid use on mantoux testing in patients undergoing screening for anti-TNF medication [abstract], Arthritis Rheum, vol.52, p.569, 2005.

J. Zou, M. Rudwaleit, J. Brandt, A. Thiel, J. Braun et al., Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab, Arthritis & Rheumatism, vol.345, issue.3, pp.780-790, 2003.
DOI : 10.1002/art.10847

M. Vigna-pérez, C. Abud-mendoza, H. Portillo-salazar, B. Alvarado-sánchez, E. Cuevas-orta et al., Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis, Clinical and Experimental Immunology, vol.168, issue.2, pp.372-380, 2005.
DOI : 10.1093/emboj/18.8.2119

F. Sallusto, J. Geginat, and A. Lanzavecchia, : Function, Generation, and Maintenance, Annual Review of Immunology, vol.22, issue.1, pp.745-763, 2004.
DOI : 10.1146/annurev.immunol.22.012703.104702

A. Catrina, C. Trollmo, E. Klint, M. Engstrom, J. Lampa et al., Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: Extended report, Arthritis & Rheumatism, vol.53, issue.1, pp.61-72, 2005.
DOI : 10.1002/art.20764

H. Mitoma, T. Horiuchi, N. Hatta, H. Tsukamoto, S. Harashima et al., Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-??, Gastroenterology, vol.128, issue.2, pp.376-392, 2005.
DOI : 10.1053/j.gastro.2004.11.060

S. Kirchner, E. Holler, S. Haffner, R. Andreesen, and G. Eissner, Effect of different tumor necrosis factor (TNF) reactive agents on reverse signaling of membrane integrated TNF in monocytes, Cytokine, vol.28, issue.2, pp.67-74, 2004.
DOI : 10.1016/j.cyto.2004.06.008